Garrett Jones
Overview
Explore the profile of Garrett Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beerman S, Dean H, Snider S, Magee T, Fitzgerald K, Ward S, et al.
Trials
. 2025 Feb;
26(1):66.
PMID: 39994760
Background: Coronary artery disease (CAD) is a global health crisis, responsible for nearly 20 million deaths annually worldwide and 12.6% of all deaths in the United States. Randomized controlled trials...
2.
Elghzali A, Swami V, Hossain M, Jones G, Babek J, Hemmerich C, et al.
Ophthalmic Epidemiol
. 2025 Feb;
:1-11.
PMID: 39908359
Purpose: To perform a systematic review and meta-analysis assessing the diversity and representation of diabetic retinopathy (DR) patients in clinical trials conducted in the United States from January 1, 2018,...
3.
Ahmed S, Altman J, Jones G, Lee T, Robertson D, Zhi W, et al.
Exp Eye Res
. 2025 Jan;
251:110231.
PMID: 39761842
Purpose: Keratin contamination is a common problem in mass spectrometry proteomic analyses, particularly in bottom-up mass spectrometry. The purpose of this study was to determine the protein contaminants introduced during...
4.
Tran A, Dennis B, Rashid M, Fitzgerald K, Jones G, Magana K, et al.
JTO Clin Res Rep
. 2024 Nov;
5(12):100713.
PMID: 39502497
Introduction: A core outcome set (COS) helps standardize outcome measurements across clinical trials. Although lung cancer is the leading cause of cancer-related deaths, research exploring COS implementation across lung cancer...
5.
Duncan J, Elfar A, Magana K, Jones G, Ward S, Magee T, et al.
Qual Life Res
. 2024 Jun;
33(8):2275-2283.
PMID: 38839683
No abstract available.
6.
Beisel A, Jones G, Glass J, Lee T, Toteberg-Harms M, Estes A, et al.
Ocul Surf
. 2024 Apr;
33:16-22.
PMID: 38561100
Purpose: Technological advancements allowing for the analysis of low-volume samples have led to the investigation of human tear fluid and aqueous humor (AH) as potential biomarker sources. However, acquiring AH...
7.
Jones G, Altman J, Ahmed S, Lee T, Zhi W, Sharma S, et al.
Invest Ophthalmol Vis Sci
. 2024 Mar;
65(3):2.
PMID: 38441890
Purpose: Tear fluid is a complex and dynamic biological fluid that plays essential roles in maintaining ocular homeostasis and protecting against the external environment. Owing to the small sample volume,...
8.
Jelinek T, Young A, Jones G, Magana K, Magee T, Ward S, et al.
Osteoarthritis Cartilage
. 2024 Feb;
32(6):713-718.
PMID: 38403154
Objective: To assess the degree of core outcome set alignment and identify issues with alignment to the 2019 COS among clinical trial registrations focused on knee and/or hip osteoarthritis (OA)....
9.
Lee T, Goyal A, Jones G, Glass J, Doshi V, Bollinger K, et al.
Database (Oxford)
. 2024 Jan;
2024.
PMID: 38284936
The aqueous humor (AH) is a low-viscosity biofluid that continuously circulates from the posterior chamber to the anterior chamber of the eye. Recent advances in high-resolution mass-spectrometry workflows have facilitated...
10.
Chaudhry M, Stadler J, Fitzgerald K, Modi J, Jones G, Magana K, et al.
Thromb Res
. 2024 Jan;
234:113-119.
PMID: 38211379
Introduction: Clinical trials (CTs) guide clinical practice, but inconsistent outcome reporting presents challenges. To increase comparability, a core outcome set (COS) was created for primary Immune thrombocytopenia (ITP) in 2009...